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ABSTRACT
Objectives: Acute lymphoblastic leukemia (ALL) represents a clonal expansion and arrest of
normal lymphoid hematopoiesis. ALL remains the most common malignancy in children. The
survival rate of the patients is significantly increased since the 1960s. This study was
undertaken to evaluate the 5- year overall survival (OS) rates of patients with ALL in a single
center in IRAN.
Methodology: A total of 220 children with ALL up to 15 years old who had been treated by
UKCCSG protocol at the Oncology Department in Shafa Hospital from March 1997 to October
2004 were evaluated for their age, gender, as well as FAB types, presenting features, outcomes
of therapy and relapse.
Results: The mean age of the patients was 6.69 years (SD= 3.8, median 6 years). In this series,
123 patients (55.9%) were male. There was a complete remission induction rate of 85.5% during
first induction course of therapy. Five-year overall survival was 60.9% and it was better (p=0.006)
in standard risk group. Relapse rate after first remission was 23.6% and death due to relapse
was more in high risk group, but it was not significant (p=0.053). There were 59(68.6%) of total
deaths in induction period and 18(20.9%) after relapse. Overall infections (69.4%) were major
cause of deaths in induction period.  OS was better in boys, age group between (1-10 yo) and
initial white blood cells count (10,000-50,000x103/mm3) but there were not significant (p=0.39,
p=0.30, p=0.202, respectively).
Conclusion: Five-year overall survival was 60.9% of the children with new ALL who were
undergoing chemotherapy by UKCCSG protocol. High mortality rate in induction period was
mainly due to infections which decreased five-year overall survival in this study.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) repre-
sents a clonal expansion and arrest at a specific
stage of normal lymphoid hematopoiesis.1 ALL
remains the most common malignancy in chil-
dren. It accounts for one fourth of all childhood
cancers and approximately 75% of all cases of
childhood leukemia.2 The peak incidence of
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ALL occurs between two to five years of age.3
Although more than 5% lymphoblast, in the
bone marrow is highly suggestive of leukemia,
a minimum of 25% blast cells is usually required
before the diagnosis is confirmed.4 Central ner-
vous system leukemia (CNS) is found at diag-
nosis of fewer than 5% of children with ALL.5
Clinically demonstrable testicular disease is
rarely present at initial diagnosis but occult tes-
ticular disease can be diagnosed by biopsy in
25% of newly diagnosed boys.6
The French-American-British (FAB) system
defines three categories of lymphoblasts.  Ap-
proximately 85% of children with ALL have pre-
dominant L1 morphology, 14% have L2 and 1%
have L3.7 Patients who are between ages one
and nine with an initial White Blood Cells
(WBCs) < 5,0000 /mm3 were defined as stan-
dard risk.1 In 1977 the Unite Kingdom
Children’s Cancer Study Group (UKCCSG) was
formed by a small number of consultants from
seven hospitals. The group has since expanded
until it now covers 20 pediatric oncology
centers in mainland Britain together with two
in Ireland.8
The purpose of this study was to evaluate the
five- year overall survival (OS) rates of patients
with ALL who were treated by UKCCSG
protocol at our department and also the related
factors.
METHODOLOGY
From March 1997 to October 2004, 220 patients
(age under 15 years) with ALL were diagnosed
and treated in Hematology/Oncology Depart-
ment at Shafa Hospital. The children were sub-
divided into three age groups: infancy < one
year olds, one to nine year olds, and 10 to 15
year olds. Their gender, sex, FAB type, clinical
features, first remission rate, relapse rate, death
in induction, death in relapse, Overall survival
(OS), Disease-Free survival (DFS), and Events-
Free survival (EFS) were compared between age
group by MINITAB 14 software.
Median follow up was seven years (range, 5
days to 12 years 6 months). Complete remission
(CR) was defined as a normocellular bone mar-
row examination containing less than 5% blast
cells. Deaths within 30 days of entry were clas-
sified as induction deaths. OS was defined as
an indication of the proportion of people within
a group who are expected to be alive after a
specified time. Disease-free survival (DFS) was
defined as measures the proportion of people
among those treated for cancer who will remain
free of disease at specified time after treatment.
Event-free survival (EFS) was defined as a mea-
sure of the proportion of people who remain
free of a particular complication of disease
(called an event) after treatment that is designed
to prevent or delay that particular complication.
In this study the patients were classified into
two risk groups, standard and high risk groups.
Standard risk patients included age between
one to nine with an initial WBC < 50,000/mm.3
High risk patients included age under one year
and over than 10 year or with initial WBC >
50,000/mm.3 A p value < 0.05 was considered
statistically significant. Relapse was evaluated
in three separate period of time, during 6
months, 6-18 months and 18 months after first
remission. The patients were treated according
to the UKCCSG protocol. The patients were
stratified within the treatment groups accord-
ing to prognostic criteria. Girls between one to
nine year of age with a WBC count less than
20,000/mm3 were scheduled to receive treat-
ment A. Patients with a WBC count greater than
100,000/mm3 were scheduled to receive treat-
ment D. Another girls and boys were scheduled
to received treatments B and C respectively.
Summary of treatment, Upon completion of in-
duction, patients were divided into four treat-
ment groups as above. All patients received the
same induction chemotherapy, utilized
Vincristine, Prednisolone, L-asparaginase,
Daunorobicine and intrathecal Methotrexate.
The drugs utilized in intensification were
Vincrisine, Prednisolone, Daunorobicine,
Thioquanine, VP16, Ara-C and intrathecal
Methotraxate. Patients were randomized to re-
ceive either one block of intensification, given
immediately after induction (treatment B), one
block of intensification administered after cra-
nial irradiation (18 Gy) at weeks 20 of mainte-
nance (treatment C), or to receive both early and
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late intensification blocks (treatment D) and in
treatment A the patients did not receive any
intensification block. A 12 weeks cycle of con-
tinuance daily Mercaptopurine and weekly
Methotrexate, with a monthly injection of Vin-
cristine followed by a short pulse of Predniso-
lone, to a total of 40 to 48 month according to
treatment group and also intrathecal Methotr-
exate on the first day of each cycle were consid-
ered as maintenance therapy. To confirm con-
tinued remission bone marrow aspiration and
lumbar punctures at the beginning of each cycle
were obligatory.
RESULTS
In the 220 patients with ALL up to 15 years
old their mean age at diagnosis was 6.69 (sd =
3.8). One hundred twenty three patients (55.9%)
were male and 97(44.1%) female. Four patients
(1.8%) were below one year, 162(73.6%) 1-9
years, 54(24.5%) 10-15 years. Comparison of
presenting features showed that fever (64.4%),
pallor (53.6%), splenomegaly (48.6%),
hepatomegaly (46.3%), lymphadenopaty (45%),
and bone pain (34%) were more frequent in chil-
dren. FAB types L1 (77.7%) and L2 (18.6) were
more frequent in the children (Table-I). Treat-
ment A was used in 38(17.3%) of the patients, B
12(5.5%), C 84(38%) and D 85(36.7%) (Table-III).
The duration from initial diagnosis to the end
of study was 12.5 years. The minimum five-year
OS, DFS and EFS for 220 patients was 60.9%,
49.1% and 11.8% respectively. For males the
five-year OS were 63.4% and for females 57.7%
(p 0.303). The five-year OS in patients below one
year were 0%, one to nine years 66% and 10 to
15 years 50%. There was no significant differ-
ence in OS with age (p=0.302), initial WBCs
count (p=0.209), FAB types (p=0.535) and treat-
ment groups (p=0.115). But there was signifi-
cant trend in OS with risk groups (p=0.006).
There was no significant difference in age at
diagnosis of ALL with gender (p=0.548), initial
WBCs count (p=0.522), FAB types (p=0.254),
CNS involvement (0.144) and first remission
rate (0.765). Relapse risk after first remission for
Table-I: Characteristics of 220 patients up to 15 years
diagnosed with ALL, 1997-2004
         Age (yo)
Parameter No. of patients <1 1-9 10-15
& %n=220 (100) n=4 n=162 n=54
Gender:
  Male 123(55.9) 1 91 31
  Female 97(44.1) 3 71 23
Clinical finding:
  Fever 144(65.4) 3 110 31
  Pallor 118(53.6) 0 91 27
  Bone pain 75(34) 1 57 17
  Lymphadenopaty 99(45) 2 66 28
  Hepatomegaly 102(46.3) 3 78 21
  Splenomegaly 107(48.6) 3 78 26
  Petechiae 33(15) 0 26 7
  GI bleeding 5(2.2) 0 4 1
  Epistaxi 9(4) 0 6 3
  Testis involvement 1(0.5) 0 0 1
  CNS involvement 12(5.4) 0 7 5
  Sweating 21(9.5) 0 15 6
  Weight lose 18(8.1) 0 13 5
  Anorexia 26(11.8) 1 17 8
  Diarrhea 6(2.7) 0 4 2
  Abdominal pain 8(3.6) 0 7 1
FAB Types
  L1 175(77.7) 2 134 39
  L2 37(19.6) 2 23 12
  L3 8(3.6) 0 5 3
Risk groups
  Standard risk 119(54.1) 0 119 0
  High risk 101(46.9) 4 43 24
Table-II: Outcomes of patients with ALL
       Age (yo)
Parameter No. of patients <1 1-9 10-15
& % n=220 (100) n=4 n=162 n=54
Survival
  Overall- survival 134(60.9) 0 107 27
  Disease-free 108(49.1) 0 88 20
  survival
  Event-free 26(11.8) 0 19 7
   survival
First remission
  Complete 188(85.5) 3 140 45
  remission
  No remission 32(14.5) 1 22 9
Deaths
  In induction 59(26.8) 2 41 16
  After relapse 18(8.1) 0 10 118
  After induction 9(4.1) 2 4 3
    Without relapse
Relapse   No. of patients
  after induction    & % n=161
Relapse 38(17.3)
  Bone marrow 26(17.3) -- 17 9
  CNS 16(9.9) -- 9 7
  Testis 3(1.8) -- 3 0
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the children who were undergoing chemo-
therapy by UKCCSG protocol was 38(23.6%) in
our study. Relapse from Bone marrow occurred
in 26(17.3%) of patient, CNS 16(9.9%) and testis
3(1.8%) (Table-II). There was no significant cor-
relation in age groups (p=0.146), initial WBCs
count (p=0.148), FAB types (p=0.506) and risk
groups (p=0.357) with relapse. But there was
significant trend in deaths after relapse with
increasing age at diagnosis of ALL (p=0.026).
There was significant correlation in CNS relapse
with age groups (p=0.043) and lymphadenopa-
thy (p=0.010). There were 86(39.09%) of deaths.
Fifty nine (26.8%) deaths occurred in induction
period, 18(8.2) after relapse and 9(4.1%) after
induction period without any evidence of
relapse (Table-II). The major causes of deaths
in induction period were sepsis 29(49.1%),
typhilytis 12(20.3%), cardiac 6(10.1%), renal
5(8.4%) and CNS 3(5%) complications. The
prognosis after relapse was better after 6 months
of remission and also in testis relapse, but it was
not significant (p=0.712, p=0.792 respectively).
Deaths after relapse was more in high risk group
but it was not significant (p=053). There was sig-
nificant correlation in first remission rate with
FAB type (p=0.006). There was significant trend
in bone pain with standard risk group (p=0.021)
and low initial WBCs count (p=0.007). Blasts
were detected on initial peripheral smear of
84(38.2%) patients with significant trend in high
initial WBCs count (p=0.001). Also there was
significant correlation in splenomegaly with
hepatomegaly (p=0.033), lymphadenopathy
(p=0.005) and risk groups (p 0.0.046).
DISCUSSION
Five year survival rate for children diagnosed
in successive calendar periods were 69% in
1980-84, 74% in 1985-89 and 81% in 1990-94. The
improvement in survival was highly significant
overall (p=0.0001).8 Survival outcomes for pa-
tients treated on successive children’s cancer
group (CCG) clinical trials conducted over the
1968-2004 period, approximately was 18%  in
1968-70 and 85% in 1996-2002.9 Survival did not
vary significantly between hospitals with dif-
ferent numbers of patients or between UKCCSG
and other hospitals during a big study of 5078
children with ALL in 1980-94 by C A Stiler et
al. For example UKCCSG 5- year survival was
82% and 79% others center during 1990-94.8 In
the 220 patients with ALL up to 15 years old
who were treated by UKCCSG protocol
five-year OS was 60.9% in our study at SHAFA
Hospital from Jondishapoor Ahwaz medical
university in IRAN as a developing country.
Complete remission induction rate of children
with ALL according to the chemotherapy
regimens is approximately 85% to 95%.10
Failure of induction therapy is a relatively rare
event, occurring in fewer than 5% of children
with ALL treated with correct regimens.11 Like
Table-III: The five-year survival rates of patients with ALL
Factors No. of % 5 year p value
Patients survival
rate (%)
Overall 134 60.9 60.9 ---
Gender 0.393
   Male 123 55.9 63.4
   Female 97 44.1 57.7
Age (yo) 0.302
   <1 4 1.8 0
   1-9 162 736 66
  10-15 54 24.5 50
Initial WBCs/mm3 0.209
  <10.000 95 43.2 63
  10.000-50.000 67 30.5 65
 >50.000 58 26.4 51
Initial Hb g/dl
  <7 90 40.9
  7-10 107 48.6
  >10 23 10.4
FAB types 0.535
  L1 175 77.7 62.2
  L2 37 18.6 54
  L3 8 3.6 62.5
Treatment group 0.115
  A 38 17.3 78.9
  B 12 5.5 33.3
  C 85 38.6 58.8
  D 85 38.6 58.8
Risk groups 0.006
Standard risk 119 54.1
  High risk 101 45.9
Relapse 38 23.6
  Relapse time
    of diagnosis
 (Months)
   <6 8 21
   6-18 13 34.2
   >18 17 44
these, reports there was a complete remission
rate of 85.5% during first induction course of
therapy in our study. Despite acceptable first
remission rate, the high mortality rate in induc-
tion period (68.6% of total deaths), reduced out-
come in our center. Investigators at St Jude
Children’s Research Hospital have demon-
strated that after successful completion of 2.5
years of therapy, approximately 80% of patients
remain free of disease.9 Similar results were
observed in a study from Great Britain that con-
cluded that patients alive 6 years after diagno-
sis without relapse have a high likelihood of
prolonged survival and cure.12
Like other studies, relapse rate after first
remission was 38(23.6%) in our study. Despite
current intensive treatments, 25-30% of children
with ALL experience bone marrow relapse.1
Bone marrow relapse rate in our study was only
26(17.3%), it shows that long- term duration of
maintenance therapy (40-48 months versus 24-
36 months) reduce the relapse rate.13,14 Long-
term survival rate in relapse after 6 months of
remission was better in our study, but it was
not significant (p=0.712). As reported by other
investigators we found that children aged 1-9
at diagnosis and those with WBCs of under
50,000/mm3 had a better prognosis and the
combination of these two factors has been pro-
posed as defining a good risk subgroup
(p=0.006).15 A slightly lower survival rate in girls
was in contrast to previous studies.16 Maybe it
is due to more attention for male gender by par-
ents in our region. There was significant trend
in bone pain with low risk group (p=0.021) and
low initial WBCs count (p=0.007) as a report by
Jonsson et al17, that initial WBCs count were
usually normal in ALL patients who had severe
bone pain. Clinical and laboratory features at
diagnosis in children with acute lymphocytic
leukemia in our study almost were like other
studies.9
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